Nasdaq apls.
Dec 1, 2023 · The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors?
Bluebird bio Inc (NASDAQ:BLUE) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. ... (NASDAQ:APLS) (after the close)That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ...WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...APLS U.S.: Nasdaq Apellis Pharmaceuticals Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 28, 2023 7:01 p.m. EST Delayed quote $ 46.50 -0.66 -1.40% After Hours Volume: 1... We challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...
CRESTWOOD, Ky. and WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...NEW YORK, Aug. 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging ...Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business …
WALTHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...Apellis Pharmaceuticals (NASDAQ:APLS) Insider Buying and Selling Activity. Current Insider Ownership Percentage 7.50%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 13. Amount Of Insider Selling (Last 12 Months) $35.44 M. Get APLS Insider Trade Alerts. Want to know when executives …
Nov 30, 2023 · Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and ...Find the latest dividend history for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.Get 7 Days Free Sign In Sign In TopicsApellis Pharmaceuticals, Inc. is a global biopharmaceutical company and is a trending biotech stock to watch in the stock market as of late. This came after the company’s EMPAVELI ...
WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...
Apellis Pharmaceuticals Insider Sold Shares Worth $444,620, According to a Recent SEC Filing. Nov. 21. MT. Mizuho Raises Price Target on Apellis Pharmaceuticals to $49 From $42, Keeps Neutral Rating. Nov. 13. MT. Goldman Sachs Initiates Apellis Pharmaceuticals at Buy Rating With $74 Price Target.
Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates ...WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five abstracts ...Nov 4, 2023 · WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ... Under priority review status, the FDA has accepted Apellis Pharmaceuticals' (NASDAQ:APLS) marketing application seeking approval for pegcetacoplan for the treatment of paroxysmal nocturnal ...
CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...May 14, 2021 · WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S ... WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Apellis Pharmaceuticals (NASDAQ:APLS) has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026.; Under the terms of ...20 de jul. de 2023 ... As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high ...
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...
Advertisement. Apellis Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View APLS financial statements in full.WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Since Friday, Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of safety events connected to Syfovre. Syfovre ...Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com. Reported EPS is $-1.17 EPS, expectations were $-0.86. Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings ...WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its third quarter 2021 ...Nov 17, 2023 · Apellis Pharmaceuticals Inc (NASDAQ:APLS) showed a performance of 4.00% in past 30-days. Number of shares sold short was 16.23 million shares which calculate 7.13 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $71.19 to the stock, which implies a rise of 32.73% to its current value. Envestnet Asset Management Inc. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,305 shares of the company’s stock after acquiring an additional 561 shares during the quarter. Envestnet Asset Management […]WALTHAM Mass. and CRESTWOOD, Ky., March 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...
Nov 16, 2023 · The public float for APLS is 97.66M, and at present, short sellers hold a 16.62% of that float. On November 16, 2023, the average trading volume of APLS was 2.69M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 0.54relation to previous closing price of 48.14.
MarketWatch IBD DJIA 35285.12 0.30% S&P 500 4554.22 0.11% U.S. 10 Yr 4/32 Yield 4.426% 0.15% Sign In Apellis Pharmaceuticals Inc. APLS (U.S.: Nasdaq) Overview News Apellis Pharmaceuticals...
Nov 29, 2023 · That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ... Apellis Pharmaceuticals, Inc. Common Stock (APLS) Institutional Holdings | Nasdaq Skip to main content Created with Sketch. Market Activity Funds + ETFs After-Hours Quotes …Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business …On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Apellis Pharmaceuticals Inc (Symbol: APLS), where a total of 7,621 contracts have ...Apellis Pharmaceuticals (NASDAQ: APLS) 2% HIGHER; BofA Securities upgraded the stock from Neutral to Buy with a price target of $85.00 (from $52.00). After-hours movers: GitLab surges on earnings ...(NASDAQ: APLS) Apellis Pharmaceuticals currently has 118,499,945 outstanding shares. With Apellis Pharmaceuticals stock trading at $61.58 per share, the total ...The public float for APLS is 97.66M, and at present, short sellers hold a 16.62% of that float. On November 16, 2023, the average trading volume of APLS was 2.69M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 0.54relation to previous closing price of 48.14.5 сент. 2023 г. ... Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a ...WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...Apellis pharmaceuticals, inc. (nasdaq:apls) saw its share price drive 177% higher over five years. Shareholders gained a total return of 0.7% in the last quarter. Apellis pharmaceuticals made a loss in the past year, but has seen revenue growth of 43% per year. The company has a good track record of growing its revenue at a compound rate of 23% ...
Apr 7, 2023 · The firm decreased its portfolio allocation in APLS by 48.09% over the last quarter. GSAOX - Goldman Sachs Small Cap Growth Insights Fund holds 13K shares representing 0.01% ownership of the company. WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ...14 дек. 2017 г. ... More from Nasdaq. 09:11. Abivax [ABVX] Rings the. Nasdaq Closing Bell. 1 day ago · 564 views. 00:34. As home to the world's most innovative and ...Instagram:https://instagram. best leverage to use in forexlabu stock forecastclover advantage plangrid etf APLS Latest Pre Market Trades About Latest Pre-Market Trades Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Nasdaq …WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its ... forex or optionspaper money trading CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. coin 1921 silver dollar value Jul 28, 2023 · As of Q1 2023, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) was the most commonly held stock out of the 12 stocks with biggest upside potential according to analysts. Its shares were held by 42 of ... 27 de set. de 2023 ... (APLS) Investors Affected by Stock Drop -- Levi & Korsinsky Pursuing Class Action Lawsuit ... (NASDAQ:APLS) investment and want to learn about a ...USA. Published on June 4, 2021. venBio, a Palo Alto, CA and San Francisco, CA-based closed its fourth life sciences venture capital fund, venBio Global Strategic Fund IV, LP, at approximately ...